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Abstract
The completion of the Human Genome Project triggered a whole new field of genomic research which is likely to
lead to new opportunities for the promotion of population health. As a result, the distinction between genetic and
environmental diseases has faded. Presently, genomics and knowledge deriving from systems biology,
epigenomics, integrative genomics or genome-environmental interactions give a better insight on the
pathophysiology of common diseases. However, it is barely used in the prevention and management of diseases.
Together with the boost in the amount of genetic association studies, this demands for appropriate public health
actions. The field of Public Health Genomics analyses how genome-based knowledge and technologies can
responsibly and effectively be integrated into health services and public policy for the benefit of population health.
Environmental exposures interact with the genome to produce health information which may help explain inter-
individual differences in health, or disease risk. However today, prospects for concrete applications remain distant.
In addition, this information has not been translated into health practice yet. Therefore, evidence-based
recommendations are few. The lack of population-based research hampers the evaluation of the impact of
genomic applications. Public Health Genomics also evaluates the benefits and risks on a larger scale, including
normative, legal, economic and social issues. These new developments are likely to affect all domains of public
health and require rethinking the role of genomics in every condition of public health interest. This article aims at
providing an introduction to the field of and the ideas behind Public Health Genomics.
Keywords: Epidemiology, Genomics, Epigenomics, Prevention, Public Health, Public Health Genomics, Translational
Research, Policymaking, Personalised Healthcare
Introduction
Only 50 years after the discovery of the DNA structure by
James Watson and Francis Crick, the scientific world com-
pleted the sequencing of the entire human genome, the
Human Genome Project. As a consequence, the field of
human genome research knew a rapid discovery phase
with international initiatives like the “1000 Genomes
project” or the “Personal Genome Project” and the devel-
opment of the necessary technological tools [1]. Further-
more, there was a rise in the research field of the -omics:
(epi)genomics, proteomics, interactomics, metabolomics,
nutrinomics... These domains of systems biology gave rise
to a better understanding of the human physiology and
pathophysiology [2].
Although the terms ‘genetics’ and ‘genomics’ are some-
times used interchangeably, they have a different mean-
ing. Genetics is the science of inheritance and focuses on
Mendelian inherited traits where mostly a mutation in
one gene causes the disease. Genomics is the study of a
complex set of genes, their expression and how they
interact with other genes and the environment to affect
how a condition develops.
Classically, there is a distinction between environmen-
tal and genetic diseases. However, this point of view has
changed. There is hardly any disease without a possible
genetic contribution. The common diseases, or the com-
plex diseases, are caused by an interplay of different
genetic, lifestyle and environmental factors. In 2006 the
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Institute of Medicine published a report in which it
pointed out a critical need for transdisciplinary research
that would integrate genomics and the biological sciences
with the behavioural and social sciences, thus joining
‘nature’ and ‘nurture’ [3].
Public health interventions have so far focussed on
environmental-specific factors principally due to scienti-
fic and technological limits. The advances brought about
by genomics are changing these perceptions. Exogenous
influences will remain of vital importance for public
health, but focussing merely on these influences may
never equal the triumphs of the past [4]. To stay success-
ful in promoting health and preventing disease, the effec-
tiveness of public health interventions must be
strengthened by incorporating all determinants of dis-
ease: the internal host-specific factors and their interac-
tions with the environment [5].
In 2005, a multidisciplinary group of eighteen experts
form Canada, France, Germany, the UK and the US
reached a consensus about how to develop genomics opti-
mally for the benefit of population health [6]. An agreed
concept for the enterprise of translating genome-based
science and technology into improvements in population
health was developed and is extensively discussed else-
where [6,7]. The experts defined Public Health Genomics
(PHG) as “the responsible, effective integration of gen-
ome-based knowledge and technologies into health ser-
vices and public policy for the benefit of population
health”. This article aims at giving an overview of the con-
cepts of PHG, based on the elements of this definition.
Thus, it will start to give an overview of the proposed
steps to be taken to implement the results of basic science
into public health benefits, followed by the role of epide-
miology and the necessary epidemiological tools. Then it
will continue by describing the use of genomics in current
and future medical and public health practices and it con-
cludes with an outline of the multidisciplinary character of
PHG. The key issues of this article are highlighted in
Table 1.
Translational research
The relation between a DNA sequence and a phenotype is
far from simple. This means that the information about
genes and DNA sequences must be translated into facts
about genetic susceptibility to disease, the interaction
between these susceptibilities and modifiable risk factors
and the impact of this knowledge on population health.
Khoury and co-workers presented a framework for the
continuum of multidisciplinary translation research in
genomic medicine [8]. The purpose is to move promising
genomic applications to clinical and public health practice
for population health benefit and consists of four phases:
T1: gene discovery to candidate health application; T2:
health application to evidence-based practice guidelines;
T3: practice guidelines to health practice and T4: practice
to population health impact [8].
T1 research starts with gene discovery. However, this
discovery alone is not enough, it has to be evaluated how
genomic discoveries can be used to develop promising
health applications. These are used either in clinical eva-
luation or in selection of effective therapeutic options. An
emerging example of T1 research is the construction of
“genomic profiles”, testing combinations of genetic var-
iants to predict increased risk of common diseases and
potentially guide interventions [9]. T1 research in geno-
mics comprises both observational studies and clinical
trials. Human genetic epidemiology plays a fundamental
role in this kind of knowledge integration. The Human
Genome Epidemiology Network (HuGENet) is a global
collaboration of individuals and organisations to assess
population health impact of human genomics variation
and how it can be used to improve health and prevent dis-
ease in populations [10]. This means that, before clinical
applications can be considered, all the accumulated knowl-
edge about a set of gene variants must be carefully
assessed, including prevalence in different populations, the
strength of the association with different disease end-
points, and interactions between gene variants and social
and environmental determinants of risk. This results in
rigorous systematic reviews and meta-analyses of genetic
associations, the HuGE reviews [11]. HuGENet further
maintains a continuously updated knowledge base, called
the HuGE Navigator which lists all the reported genetic
associations with certain traits [12].
An important application of HuGE research is the eva-
luation of clinical validity of complex genetic tests which is
embraced as T2 research [8]. Nowadays the development
and evaluation of genomic applications for use in practice
is an unregulated process. Translation of a genetic test
from research into practice starts with the identification of
the disorder to be tested for, the specific test to be used,
and the clinical scenario in which the test will be used (e.g.
for diagnostic versus predictive purposes and the popula-
tion to be tested). The genetic test can then be evaluated
in a four-step process represented by the acronym ACCE:
analytic validity, clinical validity, clinical utility and ethical,
legal and social implications [8]. Analytic validity is the
ability to accurately and reliably measure the genotype of
interest [13]. Genetic tests should have high sensitivity,
specificity and predictive values which are measured by
the clinical validity. For complex genotypes the clinical
validity of genetic tests is not clear and is likely to be poor
for individual genetic variants. This is due to the lack of
identification of all susceptibility-associated variants, their
modes of interaction with each other and the environ-
ment. Clinical utility measures the risks and benefits of the
genetic test for the management and control of the con-
cerned disease [13]. Population and clinical-based studies
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are required to evaluate these criteria for a test in diverse
populations. T2 research also comprises the evaluation of
benefits and risks in a wide range of ethical, legal and
social issues (ELSI). As genetics moves into the direction
of genomics, and as a genetic test moves into the direction
of genome-based health information, it becomes obvious
that the ACCE framework is of limited use for evaluation.
Instead, the Health Technology Assessment (HTA)
approach is already used and has been established as an
evaluation tool within the European Member States in the
last ten years [5]. This means that the end result of such
research is a systematic review and synthesis of pieces of
evidence that will support the development of evidence-
based policy and practice guidelines [8,14]. The translation
of genomics into guidelines requires a novel type of action.
New models of HTA are needed that can account for the
unique types of evidence inherent to individualised tar-
geted therapies [15]. CTA (constructive technology
assessment), for example, is a means to guide early imple-
mentation of new developments in society and has been
used to evaluate the introduction of a new diagnostic test
in The Netherlands, the 70-gene prognosis indicator
(Mamaprint®) for node-negative breast cancer patients
[16].
Phase 3 research, the translation of evidence-based
guidelines to health practice is one of the most challen-
ging problems in healthcare and disease prevention [8].
It comprises issues such as increasing the spread of
knowledge about evidence-based interventions (dissemi-
nation research), integrating these interventions into
existing programs and structures (implementation and
health services research), and widespread adoption of
these interventions by the whole range of stakeholders
(diffusion research) [8]. Additional challenges include
workforce training, public health literacy, information
systems and public participation [17].
Table 1 Challenges in Public Health Genomics and what public health authorities can do about them?
The ultimate goal of PHG
Once we understand both the genetic and environmental factors involved in the causation of a disease, and how they interact, it will be possible to
devise effective preventive interventions targeted at strata of the population with specific genotypes
Challenges Possible role of PH authorities
Translational research • Conducting systematic reviews/meta-analyses of reported genetic associations;
• Development of evidence-based policy and practice guidelines;
• Dissemination, implementation and diffusion of research;
• Monitoring population health impact
Epidemiological tools • Study how biobanks/disease registries can be extended with genomic
information
Reconciling traditional public health concerns with effective health
interventions tailored at the level of groups of individuals
• Serving as the honest broker for emerging genomic application in practice;
• Implementing evidence-based genomic applications;
• Preventing premature use, misuse and overuse of genomic applications;
• Evaluating current public health interventions using genomic tools;
• Elaborating appropriate methods to collect and monitor the genome-based
research, identifying information gaps (population and individual level),
formulating policy development;
• Systematic evaluation in different populations and individuals;
• Quantifiying the use of genetic tests and services, the quality of the tests
used, and compare this with established standards and guidelines;
• Considering to change the public health approach into looking at the
individual first, then subpopulations, followed by the population as a whole
Ethical, legal and social issues • Monitoring the implications of genome-based knowledge in a broad social
context, thereby improving consumer protection;
• Ensuring the confidentiality, privacy and autonomy of the population;
• Establishing management pathways that describe the process of feedback of
research information to people enrolled in biobanks/registries that uses
genomic information;
• Ensuring the proper education of first-line caregivers, physicians, researchers
working with human genomics data and the general population, to ensure that
valid information reaches the population;
• Taking an active role in the transformation of current biobanks to genomic
biobanks;
• Participate actively in updating the informed consent process (proper
counselling session, discussing the possible outcome for relatives, the possibility
to withdraw from the study, international digital datasharing, feeding back
research results...);
• Encountering the possibilities of social inequalities in health, (possibly)
introduced by genome-based knowledge;
• Merging the competing interests of all different stakeholders into a
collaborative framework that rewards both scientific innovations and
appropriate clinical applications
Cleeren et al. Archives of Public Health 2011, 69:8
http://www.archpublichealth.com/content/69/1/8
Page 3 of 12
The last phase of the continuum of translation research
assesses how the adoption of evidence-based recommen-
dations and guidelines can make an impact on real-world
health outcomes [8]. T4 research often focusses on clini-
cal and public health outcomes. Additionally, the popula-
tion health impact should be monitored constantly.
Therefore, in different populations there has to be a sys-
tematic evaluation of the added value of using genetic
information on health outcomes (in terms of attributable
risks); the scope and the purpose of using genome-based
services; and the quality of the genetic information and
counselling services [4,5,8].
Nowadays, there are more than 350,000 published
human genetics and genomics articles, but it is estimated
that less than 3% deals with translation research T2 and
beyond [8]. This means that evidence-based guidelines
are very uncommon, and T4 research is even hardly
done. Although moving scientific discoveries into policy
and practice and the delivery of population-level health
benefit has always been slow and difficult at best, many
believe that this is a doable project when all relevant sta-
keholders on all levels are involved [5,18].
Role of epidemiology
One of the main contributions of genetic epidemiology is
to have a more thorough understanding of the causes of
complex diseases by taking notice of the genetic contri-
bution to those disorders [4]. To date, many of the pro-
posed advances resulted from genetic epidemiological
research made use of methods like the investigation of
familial clustering, twin, adoption and migration studies.
The specific genetic determinants have been identified
through linkage analysis and, more recently, through
genome-wide association studies (GWAS). The national
institutes of health defined a GWAS as a study of com-
mon genetic variation across the entire human genome
designed to identify genetic associations with observable
traits [19]. These studies use high-throughput genotyping
technologies to assay hundreds of thousands of single-
nucleotide polymorphisms (SNPs) and relate these
genetic variants to diseases or health-related traits [19].
The molecular and cellular processes, which are encoded
by the DNA sequence and thus possibly by the consid-
ered SNPs, are susceptible to influences from the external
environment. Therefore, besides establishing the gene-
disease association, studies on the gene-environment
interaction must be addressed. Recently, the Gene Envir-
onment Association Studies (GENEVA) consortium was
initiated to address these issues [20]. One important dis-
advantage of GWAS is the occurrence of false-positive
and false-negative associations. Therefore, the last part of
a GWAS should be the replication of identified associa-
tions in an independent population sample [19]. Addi-
tionally, knowledge of genetic variants can be used to
establish the causal nature of environmentally modifiable
risk factors, through the application of “Mendelian ran-
domisation” [18]. The basic principle in such studies is
that if genetic variants either alter the level of or mirror
the biological effects of a modifiable environmental expo-
sure that itself alters disease risk, then these genetic var-
iants should be related to disease risk to the extent
predicted by their effect on exposure to the risk factor
[18]. Because observational studies are prone to con-
founding, this can be a more reliable way to address
environmental risk factors of disease. Furthermore, mole-
cular epidemiology and systems epidemiology based on
basic genomics research, epigenomic patterns and gen-
ome-environmental interactions are promising new
developments in the field of epidemiology [21].
Although the GWAS often offer robust associations
between certain SNPs and complex diseases, the popula-
tion implication of findings from many such studies are
unclear because basic population-based genetic prevalence
data are often unavailable [22]. Population-based research
is essential to quantify the population prevalence of
genetic variants, the magnitude of disease risk associated
with these variants (in relative and absolute terms), the
contribution of these variants to the occurrence of disease
in different populations (attributable risk), the existence of
gene-environment and gene-gene interactions and the
validity of genetic tests based on such variants in predict-
ing disease risk [10,23]. One of the aims of the HuGE
reviews is to promote the completion of reviews, which
are peer-reviewed, systematic synopses of the epidemiolo-
gical aspects of variation in particular genetic variants and
health outcomes [11]. A major future challenge is to
rethink these approaches in the light of personalised medi-
cine and healthcare: the more evidence is provided on the
individual (personal) level, the less evidence can be
expected on the population level due to interindividual
genomic variation including individual epigenomic effects.
Genetic epidemiology research relies heavily on rou-
tine health records such as electronic patient records or
disease registries for the identification of disease cases,
controls or risk factor information and risk patterns.
Whereas the use of routine datasets for genetic research
is well established the opposite has not taken place; that
is, the contribution of routinely collected data to trans-
late findings from research into population health activ-
ities such as surveillance, needs assessment, health
promotion and disease prevention programmes and eva-
luation [24]. Anyhow, epidemiological approaches are
fundamental to the population-based biobanks being
proposed for gene discoveries and characterisation, as
well as to large case-control studies of common diseases
using whole genome association analyses [25,26].
The discussion about the relevance of integrating gen-
ome-based information into biobanks and about the role
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of genome-based biobanking for epidemiological research
and public health is still in its early stages [26]. In the
meantime, various cancer registries and neonatal screen-
ing programmes have expanded their existing databases
with genotyping to study disease incidence and preva-
lence, natural history and risk factors. In addition, huge
amounts of biological materials are collected to quantify
disease incidences in various populations and subpopula-
tions and to gain an insight into the risk factors, includ-
ing genome-environment interactions. These biobanks
are based on large cohort studies (for example in the UK
[27]), or even concerned a whole population (for example
in Iceland [28]). Nevertheless, the majority of existing
biobanks are still relatively small collections of tissue
samples related to specific diseases such as cancer.
The future challenges for biobanks with respect to epi-
demiological research and public health are numerous.
They include the incorporation of genomics into existing
public health programmes and the integration of gen-
ome-based knowledge into future surveillance systems
[26,29]. Thus we can explore the use of existing data
sources to enhance the contribution of genomics to
population health [24]. Possibilities are abundant. One
plain example is disease surveillance. Genomics forms an
essential part of public health work to combat infectious
diseases. Sequencing of pathogens, for example, can
allow rapid diagnosis and control of disease. To under-
stand the host response to pathogens and the association
of genetic variants with susceptibility or resistance to dis-
ease, human genomics research is of great value. But rou-
tine datasets are also central to the surveillance of non-
infectious disease and here too, the understanding of
genomic health determinants as a factor in disease devel-
opment will be essential. Screening for genetic disease,
although by biochemical methods, was already initiated
in the early 1960s with phenylketonuria testing and appli-
cation of the Guthrie test in newborns [30]. Most genetic
screening programmes today are limited to single gene
and chromosomal disorders and entail different aims like
the identification of affected individuals through neonatal
or antenatal screening or pre-conceptual testing of cou-
ples. Routine databases could also play a role in persona-
lised disease prevention programmes by assisting the
identification and targeting of patients in the various
screening groups and the management and evaluation of
programmes [24]. In the future it could be interesting to
link the individual information during the whole life
span, with the aid of the electronic patient records [26].
Personalised medicine
Concrete applications of genomics in public health,
especially based on GWAS, are most pronounced in the
field of pharmacogenetics and pharmacogenomics [31].
These themes originated by the notion of the existence
of large interindividual differences on drug reaction. A
certain drug can have a therapeutic effect on some, but
can be ineffective in others and certain people show
adverse drug effects on a dose which is subeffective by
others. Pharmacogenetics is based on the principle that
it is time to use the right drug in the right dose in the
right patient at the right time using integrated clinical
and genomics parameters [32]. One well-known thera-
peutic example is the selected use of Trastuzumab, only
in patients whose breast tumour expresses the her2/neu
gene [33]. The recommendation of the FDA to select
the starting dose of Warfarin to reduce the risk of
thromboembolic events based on CYP2C9 and VKORC1
polymorphisms is another example of a well-introduced
application of genomics into clinical practice [34]. Apart
from these, the number of examples based on GWAS in
pharmacogenomics are increasing (see the recent review
of Wang et al [31]). However, although pharmacoge-
nomics acknowledges the central role of the genetic
constitution of a patient to drug metabolism, numerous
other factors alter drug response including other drugs,
environmental and physiological factors such as nutri-
tion, ageing, liver and kidney function and patient com-
pliance, which in the end results in the understanding of
individual pathways in systems biomedicine.
Personalised medicine is the translation of the science
of pharmacogenomics and other individualised interven-
tions into clinical practice [35]. Personalised medicine
involves preventive, diagnostic, and therapeutic interven-
tions, with risk defined through genetics as well as clini-
cal and family histories. An example is genetic testing to
determine the risk of breast cancer. Women carrying a
certain BRCA1 mutation have a cumulative risk of 65%
by the age of 70 years to develop breast cancer [36].
However, currently there are no standard criteria for
recommending or referring someone for BRCA mutation
testing. Candidates for BRCA genetic testing are identi-
fied through careful analysis of the family history, the
patient’s ethnic group and the pathologic features of the
breast cancer [37,38]. Further studies on the genetic hall-
marks of breast tumours indicated that early and inher-
ent genetic properties of the tumour entail the tumours’
ability to metastasise [39]. A Dutch research group iden-
tified a gene-expression profile, based on 70 genes, that
turns out to be a powerful predictor of disease outcome
in young patients [40]. This will allow clinicians to select
patients who would benefit from adjuvant systemic treat-
ment, reducing the rate of both overtreatment and
undertreatment [40].
Expectations about the future impact of the discoveries
through the GWAS on preventive and clinical health care
practice are high. Despite the current euphoria, the predic-
tive value of genetic profiling is still limited for most com-
plex disorders [41]. This is because most individual gene
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variants associated with common diseases will have low
positive predictive value and associated attributable risk
[7]. Also, for some known markers much remains to be
learned about their contribution to the incidence of dis-
ease [42]. For example, homozygotes for the APOE ε4
gene variant suffer from an increased risk of Alzheimer’s
disease, but many people who test positive for this allele
will not develop Alzheimer’s disease [7]. In fact, fewer
than 30% of people with the APOE ε4 polymorphism
develop Alzheimer’s disease [43]. Thus, notwithstanding
the growing availability of commercial, direct-to-consumer
genetic testing via the internet, evidence-based applica-
tions of genetic profiling in clinical and public health care
practice are still a far future prospect. Nevertheless, cur-
rent dynamic developments such as in systems biology,
epigenomics and the Personal Genome Project (PGP) ask
for different approaches having the potential for persona-
lised medicine and healthcare, since they provide insights
and evidence on the individual level [2]. Most of the scien-
tific attention should, therefore, be focussed on basic
genomic research, unravelling the understanding of com-
mon diseases in all its complexity and all its interactions
[41].
Public Health
About the role of genomics in improving public health
some scepticism has been raised. Some authors have sta-
ted that genomics undercuts efforts to address social and
environmental causes of ill health [25]. Some reject geno-
mics research as an unwarranted extension of the indivi-
dual risk paradigm [44]. The challenge in Public Health
Genomics is to reconcile traditional public health con-
cerns, such as equity and access to health for all popula-
tion groups, with safe, effective health interventions and
diagnostics tailored at the level of each individual. To
address the role of human genomics in improving popu-
lation health Khoury et al. defined three priorities [45]: 1)
serving as the honest broker for emerging genomic appli-
cations in practice; 2) implementing current evidence-
based genomic applications to improve health and pre-
vent disease, while discouraging premature use, misuse,
and overuse of genomic applications and 3) using geno-
mics tools to evaluate the health impact of public health
interventions regardless of whether they currently use
genomics.
Population-based data on genome-disease associations
and genome-environment interactions form the basis for
studying the added value of genome-based health informa-
tion to existing recommendations for disease prevention.
They will help to gain more insight in the contribution of
genomic variants to common diseases. Public health agen-
cies must, in the meantime, work out the appropriate
methods to collect and monitor the results of genome-
based research and technologies to identify information
gaps on the population as well as on the individual level
and to formulate the policy development of evidence-
based strategies in this domain [26].
Systematic evaluation is critical for improving, account-
ing for and prioritising public health actions involving
genomics. Public health must therefore evaluate the
impact of using genetic information on morbidity, dis-
ability and mortality associated with disease in different
populations and individuals [2,4]. Genetic work is mostly
undertaken in outpatient departments, either within clin-
ical genetics, or by the specialty concerned with the
ongoing clinical care of the patient (for example paedia-
trics, neurology, cardiology, oncology etc). The need to
quantify such activity, including the magnitude and
determinants of the utilisation of genetic tests and ser-
vices, and the quality of genetic tests and clinical and pre-
ventive services relative to established standards and
guidelines, is vital for needs assessment, review and eva-
luation of services, and for the quantification of unmet
needs and assessment of service inequalities [4,14,24].
Based on these needs, the future challenge for epidemio-
logical research and public health include the incorpora-
tion of genomics into existing public health programmes
[26]. Furthermore, whereas the concept and use of
“genetic tests” may not reflect the complexity of most
diseases, much more plausible and practicable seems to
be the concept and use of “genome-based information”,
since it is based on the understanding of genome-envir-
onmental interactions changing over time and space
within individuals. In the landscape of Public Health
Genomics these two different approaches and ways of
thinking can already be observed: whereas institutions
such as the Public Health Genomics Foundation (PHGF)
in the UK or the Institute of Public Health Genetics in
Seattle, USA, focus on the role of genetic tests for public
health, other institutions such as the Institute for Public
Health Genomics in Maastricht, The Netherlands, the
European Centre for Public Health Genomics (ECPHG)
or the Public Health Genomics European Network
(PHGEN) focus on the role of genome-based health
information including information from systems biology,
epigenomics and the Personal Genome Project for public
health.
The potential for genomics to promote public health in
case of smoking is a helpful example to illustrate the cur-
rent usefulness, threats and limitations of these applica-
tions. Smoking-induced lung cancer continues to be a
major public health concern. However, it is widely
known that smoking cessation will lead to a decreased
risk of lung cancer and other smoking-related diseases
such as chronic obstructive lung disease, coronary artery
disease, asthma and other smoking-related conditions
[46]. For years, cessation programmes targeted the indivi-
dual smoker with a limited but tangible success. From a
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public health perspective, societal-level approaches such
as bans, taxes and antismoking campaigns showed a
more substantial utility. These methods have a dual bene-
fit: they decrease the smoking prevalence, and in the case
of smoking bans, they prevent the exposure of vulnerable
populations to secondary smoke. The emerging question
today is how genomics could augment those public
health effects [47]. First of all, genome research can iden-
tify genotypes that modulate smoking status, initiation,
cessation, quantity and treatment response. In addition,
the discovery of polymorphisms linked to an altered risk
of lung cancer would be valuable. Secondly, genetic test-
ing could lead to an increased rate of smoking cessation.
The first mechanism Carlsten et al proposed for this is
that if a smoker is aware of a higher risk of lung cancer, he
or she will have a much greater motivation to stop [47].
Furthermore, genetic testing could identify individuals
who should be subjected to more intensive cessation pro-
grams. Determining whether these two approaches pro-
vide a public health benefit requires attention to two
questions. First, how does genomic knowledge improve
existing individual or societal interventions? And second,
will the augmentation in cessation rates due to genetic
testing justify the risks? Some drawbacks and risks asso-
ciated with genetic testing could be hypothesised too. For
example, the knowledge of having an adverse polymorph-
ism could lead to substantial anxiety. The lack of cessation
success could be blamed on genetic factors and someone
could therefore lose the remaining motivation to quit. The
opposite could be true too. If a genetic test shows no
increased risk of smoking related diseases, it could be seen
as a justification to start or to keep on smoking. And it
could serve the tobacco industry as a defence against liabi-
lity. One could imagine misleading marketing campaigns
such as “Is cigarette smoking safe for you? This test can
help you decide.” This shows that the potential harms are
significant. However, there is a motivation to study the
genetic components of all smoking aspects. It will lead to
a better understanding of the underlying mechanisms of
substance abuse and could lead to innovative therapeutics
with applicability beyond smoking. Furthermore, it could
reveal novel signalling pathways that contribute to the
onset of lung cancer and other smoking associated ill-
nesses. Although genomics studies could be acknowledged
as currently unlikely to lead to a reduction of lung cancer
compared with the proven, non-genetic-based strategies
for smoking cessation, our smoking behaviour is not only
influenced by social factors, but also by our genomic
make-up with its multiple variants. If for example, we try
to empower people to stop smoking, we see that there are
people for whom it is almost impossible to quit, and today
we know that to a large extent this may be due to genomic




Public health aims at improving the health of the entire
population by implementing preventive strategies. Of
course, in the end, behind the entire population is the
individual. The progress made in genomic research of
common diseases increases the interaction and the inter-
dependence between the traditional healthcare system
and the public health system. In other words, the interac-
tion between focussing on treatment of individuals and
on prevention and control in populations is growing.
One of the main issues of PHG is how to reconcile the
notion of increased personalised medicine and healthcare
with public health interventions at population level. This
distinction was first set out by Geoffrey Rose who, how-
ever, was careful to present these approaches as comple-
mentary rather than mutually exclusive [49].
One of the promises of individualised medicine is the
possibility of engaging in a level of preventive care that far
exceeds current abilities. Screening programmes are, by
their very nature, inefficient because an entire population
is subjected to screening while relatively few individuals
benefit and some are actually harmed. This inherent ineffi-
ciency is expensive for both the individual (in terms of
morbidity) and for society (in terms of costs) [50]. Thus,
there is the potential for more target-oriented and strati-
fied prevention strategies to finally replace the ‘one size
fits all’ approach [51]. This is also reflected in one of the
general objectives of the first phase of the Public Health
Genomics European Network: the sharing of experience in
health risk reduction policies aiming at applying stratified
strategies instead of ‘one strategy for all’ [52]. Thus, there
is the possibility to avoid ineffective preventive strategies.
There is already the challenge to differentiate between per-
sons, who will respond to certain vaccinations and those
who will not. The recommended BCG vaccination is a
remarkable example. In children with an interferon-
gamma receptor deficiency, this vaccination can cause a
disseminated BCG infection which may be lethal [53].
The ultimate goal of public health genomics is, once we
understand both the genetic and environmental factors
involved in the causation of disease, and how they interact,
to devise effective preventive interventions targeted at
individuals with specific genotypes [54]. The field of epige-
nomics is expected to contribute a lot to this goal. Its
main attempt would thus not concern the new technologi-
cal advances such as gene therapy but subcategorising
populations compatible to the effectiveness of preventive
environmental interventions stratified according to their
genetic risk. The rationale behind this strategy is that the
molecular and cellular processes, which are encoded in
the gene sequence, are susceptible to influences from the
external environment [54]. Anyhow, the genetic associa-
tion studies will likely lead to population-wide health
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protection and disease prevention efforts, and not only to
targeted interventions based on genetic susceptibility [55].
Taking these new developments into account, the
assurance of the complementary nature of individualised
and population-oriented interventions within the health-
care systems, which has already been stressed by Geoffrey
Rose decades ago, appears to be even more valid than
ever before. Nevertheless, there is a huge paradigm shift
for public health. Whereas prevention strategies will turn
more and more towards secondary prevention and pri-
mary prevention might become a questionable concept,
health protection and health promotion messages will be
even more general. In the end, the task of public health is
to assure both strategies on the population level. The
major shift is that both strategies can only be effective if
they start with looking at the individual first, behind
whom might be a subpopulation and even the whole
population. That means that our current public health
approach looking at the population first and then divid-
ing it into subpopulations might be obsolete very soon.
Multidisciplinary character of PHG
Public health genomics is an interdisciplinary research
field which tries to bring together different disciplines like
the medical sciences, statistics, biotechnology and engi-
neering, pharmaceutical research and industry, policy writ-
ing departments, ethics, law, sociology, public health
practitioners, genetic centres, governments, representatives
of patient groups etc. One of the challenges in the evalua-
tion of genomic applications to healthcare is the integra-
tion of studies of the normative, legal economic and
governance implications (ELSI). These ethical, legal and
social issues are somewhat arbitrary categories, because
these issues are almost always intertwined. As corner-
stones of ethical medical research practice the fundamen-
tal rights of the individual, such as privacy issues and the
person’s autonomy, deserve unbiased attention in PHG
too. However, the public health perspective asks for princi-
ples going beyond the development of responsible health
policies and frameworks (PHELSI). It must also be consid-
ered that information of the individual genome will har-
bour information of the genetic constitution of the parents
and indirectly from other family members too. This raises
again issues of confidentiality, privacy and the ‘right (not)
to know’ [5,56]. Indeed, feedback of findings is an impor-
tant part of building and maintaining public trust in
research [57]. Feeding back research results from geno-
mics studies is complicated by a number of factors. The
most significant one is that a GWAS is a research tool and
is not designed for clinical diagnosis [57]. Although the
clinical value of the genome in general will expand, many
of the discoveries of whole genome methods currently
identify genetic variants that are responsible for very small
increases in disease risk. In such situations, there is a need
for management pathways to determine whether or what
information is fed back, who is responsible for feeding
back results, and whether this also extends to other family
members [57,58]. In general, the results offered should be
scientifically valid, confirmed, and should have significant
implications for the subject’s health and well-being [58].
Another privacy issue is related to biobanking [26]. To
date, biobanking and public health surveillance have been
looked at independently from each other [59], resulting in
the fact that existing databases, created for other purposes,
are not that easy to extend with genomic information. In
the case of genomic biobanking, it will, for example, not
be possible to render data completely anonymous because
it requires an ongoing contribution of the research sub-
jects and the linkage of old and new information. This
brings along the problem of consent. Concerning existing
databases, the involved individuals, families and commu-
nities or populations may not have explicitly consented to
(future) studies on the relationship between the human
genome and susceptibility to the disorders being studied
in that particular database [59].
In this light, (digital) data sharing becomes a potential
problem, too. Scientific policies tend more and more to
incorporate open access guidelines. This raises a number
of ethical issues as many of the principles and procedures
in medical research are not designed for wide-scale data
sharing or public health purposes [57]. Therefore, the
form of informed consent should be updated [58]. The
enrolment of study participants should start with a proper
counselling session, which requires a thorough training for
physicians and other health professionals. The consent
form should, for example, contain information about the
return of data and the possible implications for family
members [58]. Also the ability to withdraw from subse-
quent studies must be well considered, especially when the
data are released into a publicly accessible database [58].
This all means that policy makers must be aware of the
current challenge to improve consumer protection and to
monitor the implications of genome-based knowledge and
technologies for health, social and environmental policy
goals [4]. Furthermore, it might be necessary to rethink
our current governance frameworks in the light of the
new developments in genomics [60,61].
There still is a discussion about stigmatisation and dis-
crimination due to the predictive power of genetic infor-
mation [56]. Although the idea of ‘genetic determinism’
and the ‘geneticalisation of society’ are obsolete [62], the
most commonly expressed fear is that genetic informa-
tion will be used in ways that could harm people [63]. It
also has to be stressed that public health genomics has
nothing to do with modifying genes. A genetic marker is
‘just’ another modifier to explain the likelihood of devel-
oping a disease. It deserves no ‘status apart’ just because
it was gained with the aid of molecular diagnostic
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techniques [56,62]. However, it should be emphasised
that genetic information should be considered as a highly
sensitive group of medical information [5]. In the end,
with the use of predictive genetic tests, it will turn out
that ‘we are all at risk for something’. This involves the
first potential for social inequalities in health, namely the
accessibility of the tests, if the genetic tests are not reim-
bursed by the health insurances, which will lead to a two-
tire system [62]. Another source of social inequality or
discrimination will depend on the degree of understand-
ing and genomic literacy, that is being able to make
sound decisions about the risk calculation by the com-
mon population [62]. To return to the example of smok-
ing, it might be possible that healthcare systems focus
efforts only on those at highest risk of developing smok-
ing-related disorders and neglecting others. Physicians
might be less motivated to encourage cessation in those
smokers who have a genetic profile that predicts poor
response to multiple treatment modes [47]. This is what
has been called the “double-edged sword” of genetics,
because it can be considered that implementing geno-
mics in public health can result in either the widening or
the narrowing of health disparities among the population.
The major factor that determines the rate of evolution
is the social context and the degree to which society
and individual citizens concur with the research agenda
[64]. A systematic review concerning the current infor-
mation of genetic health services for common diseases
identified that consumers have vague and divergent
notions about the value of genetic testing for common
disorders [65]. The same review indicated that the pri-
mary care workforce, that will be required to be on the
front lines of the integration of genomics into practice,
feels underprepared to do so. Their inability to provide
appropriate counselling for their patients is due to this
lack of basic knowledge about genetics and their lack of
confidence in interpreting familial patterns of disease
[65]. A 2003 report by the Institute of Medicine identified
genomics as a priority for the training of all public health
professionals in the 21st century [66]. Therefore, the pub-
lic health community has a major role to play in raising
the level of general genomic literacy, developing targeted
messages about the uses of genetic information in disease
prevention and coordinating communication strategies
with stakeholder groups [4]. Craig Venter’s research
group already called for the scientific communities to be
in continual conversation with the entire society [67].
And again, new developments in genomics such as
derived from systems biology, epigenomics and the Per-
sonal Genome need to be taken into account in order to
be able to truly benefit from genomics information as
part of health information. Furthermore, individuals now
have access to their own genomes through direct-to-
consumer genetic testing companies. These events
outside medical research cannot be ignored, as there is
the potential for them to have an effect on the medical
research context, which in the case of an unfavourable
event could undermine the public trust and support that
is necessary for medical research to continue and to
thrive. Thus, the challenges we are facing should be con-
sidered in the light of events occurring in the broader
social context [57].
An underdeveloped topic in public health ELSI
(PHELSI) discussions is how medicine and public health
might approach ethical questions differently. Therefore,
Thomas et al. [68] applied the 12 principles of the public
health code of ethics to genomics. Ethical questions in
public health often address the tension between the right
of individuals and the good of the overall community,
democratic processes in determining health policies, the
prevention of conditions that lead to poor health, and the
protection of disenfranchised or marginalised popula-
tions. Bioethics appears to have a sound and systematic
foundation: it rests on the four pillars of principlism
(beneficence, non-maleficence, autonomy and justice)
[67]. Placing principlism’s thinking in a larger perspec-
tive, the broadest and most important question is
whether the public’s health is actually improved by the
knowledge derived. This brings us back to the phase 2
translational research as pointed out above, again indicat-
ing that all issues involving the introduction of genomic
knowledge into public health practice are intertwined.
To conclude, in order to succeed, the competing inter-
ests of different stakeholders have to be managed and
reconciled in a collaborative framework that rewards
both scientific innovations as well as appropriate clinical
and public health applications. In the short run, we need
to develop a policy framework that imposes accurate
laboratory testing, and truth in advertising about poten-
tial health benefits, protection from untoward psycholo-
gical or social effects, as well as reimbursements of
genome-based services that can benefit individuals,
families and populations [55].
Conclusion
Today, the mounting accomplishments of the Human
Genome Project and further developments in genomics
demand that we rethink the role of genomics in every con-
dition of public health interest. This requires a conceptual
shift in both public health and medicine [5]. As a conse-
quence, Brand et al. described a dichotomy: genomics
needs to understand how it can include public health
aspects in its work programme while public health needs
to analyse how genomics changes the concepts of public
health. As the name implies, the second approach is seen
as the core task of PHG [5].
Many papers spelled out prospects and major benefits
of genomic medicine even in the near future [42].
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However the extent to which this increased understand-
ing will lead to measurable improvements in human
health is as yet unclear but that it is likely to do so
sounds very plausible. The unknown factor is the time
scale of such advances [64]. An important and early role
for PHG will be to counter the hype that accompanies
much of the genome-based research. In addition, it has
to stress the importance of ensuring that any new test
or intervention arising from genomics research is not
introduced too soon but is comprehensively evaluated
and supported by evidence [54]. However, Khoury et al.
estimated that nowadays less than 3% of the research
deals with translation phases T2 and beyond [8].
The greatest potential public health benefit from geno-
mic profiling lies in improving common disease preven-
tion [18]. However prospects for this type of prevention
are few. The main problem is that very few common
genetic variants are known to increase risk of common
diseases substantially [18]. Even when a genetic risk is
substantial, knowledge of the risk contributes to
improved health outcomes only if effective measures are
available for preventive or early treatment [7]. Similarly,
genetic testing is of uncertain value when the available
interventions are not genotype-specific. Furthermore, for
a genetic test to be useful in the management of a com-
mon disease, it must have predictive powers over and
above accepted risk factors which can easily be measured
[18]. Genetic testing will have its greatest public health
value when it identifies individuals who would benefit
from specific interventions based on their risk [7,54]; and
especially when this risk is understood as a risk pattern
based on individual genome-based health information
instead of the narrowed idea of a genetic test.
Ultimately, the translation of advances in genome
research to routine patient care will require an educated
population and educated healthcare professionals. This
barrier should not be underestimated [42]. Therefore,
the impact of genomics in the future calls for a strategy
to develop a public health workforce that is adequately
prepared. Thus, a major goal for the public health insti-
tutions should be to create an infrastructure that sup-
ports implementation and evaluation of genome-based
activities, dissemination of genome-based health infor-
mation and education [23]. Cho already pointed out in
1999 that exactly because it was only the development
stage of genomic research, there is a valuable opportu-
nity to lay out and refine relevant ethical issues [69].
Although we are twelve years later there is still a need
for more empirical methodologies so that the available
bioethics and policy frameworks recognise that one size
will not fit all, and that the context in which a candidate
genomics application is used also matters. Policy or
other interventions should clearly define the issues that
are raised and ought to be targeted when addressing the
bioethics impact.
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